Adamas Pharmaceuticals

Adamas Pharmaceuticals discovers and develops therapies to improve the daily lives of people affected by chronic neurologic disorders. The Company pioneered a platform to develop medicines for chronic neurologic disorders, which is built upon its understanding of time-dependent biologic processes responsible for specific disease activities and drug response.

Adamas Pharmaceuticals' lead product candidate, ADS-5102, is a high-dose amantadine therapy in development for the treatment of levodopa-induced dyskinesia in people with Parkinson’s disease. It is also investigating ADS-4101, modified-release lacosamide capsules, for the treatment of partial-onset seizures in patients with epilepsy.

Additionally, Adamas' licensed assets for the treatment of moderate to severe Alzheimer’s disease, Namenda XR® extended-release capsules, and Namzaric® capsules, are currently marketed by Allergan.

Revenue(FY, 2016)

$572 K

Market capitalization(2018-06-14)

$741.2 M

Type

Public

Emeryville, US

Founded

2002

Size (employees)

84 (est)+16%

Website

adamaspharma.com

Adamas Pharmaceuticals was founded in 2002 and is headquartered in Emeryville, US

Report incorrect company information

Key People/Management at Adamas Pharmaceuticals

Gregory Went

Chief Executive Officer & Chairman

Alf Merriweather

CFO

David Mahoney

Director

Report incorrect company information

Adamas Pharmaceuticals Office Locations

Adamas Pharmaceuticals has an office in Emeryville

Emeryville, US (HQ)

750 1900 Powell St

Show all (1)

Report incorrect company information

Adamas Pharmaceuticals Financials and Metrics

Adamas Pharmaceuticals Financials

Adamas Pharmaceuticals's revenue was reported to be $572 k in FY, 2016 which is a 70.1% decrease from the previous period.

Summary

USD
Net income (Q1, 2018)	(35 m)
EBIT (Q1, 2018)	(31 m)
Market capitalization (14-Jun-2018)	741.2 m
Closing share price (14-Jun-2018)	27.5
Cash (31-Mar-2018)	50.9 m
EV	797.4 m

Adamas Pharmaceuticals's current market capitalization is $741.2 m.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	55.8 m	1.9 m	572 k
Revenue growth, %		(97%)	(70%)
General and administrative expense	15.5 m	23.5 m
R&D expense	21.9 m	35.9 m	31.2 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Revenue	176 k	25.2 m	215 k	226 k	398 k	768 k	175 k	222 k	138 k		2 k
Cost of goods sold													25 k
General and administrative expense	3.1 m	3.3 m	4.4 m	4.9 m	5.8 m	5.8 m
R&D expense	2.8 m	5.2 m	5.4 m	7.5 m	8.7 m	10 m	7.5 m	9.2 m	7.4 m	7.1 m	7.2 m	6.5 m	7.2 m

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Cash	61.4 m	33.1 m	23.7 m
Accounts Receivable	524 k	1.3 m	794 k
Inventories	645 k	5.1 m	2.5 m
Current Assets	123.5 m	113.2 m	117 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Cash	79.8 m	144.6 m	137.5 m	29.2 m	37.9 m	37.1 m	98.4 m	109.3 m	9.8 m	20.9 m	33.6 m	22.1 m	50.9 m
Accounts Receivable	251 k	218 k	120 k	485 k	361 k	936 k	461 k	860 k	769 k	1.7 m	34 k	3 k	1.6 m
Inventories												425 k	2.5 m
Current Assets	80.6 m	145.8 m	138.9 m	115.5 m	126.4 m	105.5 m	169.6 m	163.3 m	110.4 m	115.2 m	130.2 m	127 m	206.1 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Net Income	10.2 m	(51.8 m)	(60.1 m)
Depreciation and Amortization	155 k	435 k	808 k
Inventories	(97.8 m)	(153.7 m)	2.1 m
Accounts Payable	1.5 m	(788 k)	502 k

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q1, 2018
Net Income	(6.4 m)	16.4 m	(9.6 m)	(12.2 m)	(14.1 m)	(14.9 m)	(13.8 m)	(16.9 m)	(14.4 m)	(16 m)	(35 m)
Depreciation and Amortization											383 k
Inventories											(558 k)
Accounts Payable		3.3 m	3 m	3.8 m	3.9 m	2.9 m	3.5 m	4.7 m	6 m	3 m	3.9 m